BreastCare
Multidisciplinary Journal for Research, Diagnosis and Therapy

Clinical Information

DOI: 10.1159/000489329

Clinical Information

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018

Cornelia Liedtke[a] Christian Jackisch[b] Marc Thill[c] Christoph Thomssen[d] Volkmar Müller[e] Wolfgang Janni[f] on behalf of the AGO Breast Committee*

[a]Klinik für Gynäkologie mit Brustzentrum, Charité – Universitätsmedizin Berlin / Campus Mitte, Berlin, Germany; [b]Klinik für Gynäkologie und Geburtshilfe, Sana Klinikum Offenbach, Offenbach, Germany; [c]Klinik für Gynäkologie und Geburtshilfe, Agaplesion Markus Krankenhaus, Frankfurt/M., Germany; [d]Universitätsfrauenklinik, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany; [e]Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; [f]Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany

BreastCare
Multidisciplinary Journal for Research, Diagnosis and Therapy

Clinical Information

DOI: 10.1159/000489329

Supplemental Material: Appendix

Members of the 'AGO Breast Committee' in alphabetical order: U.-S. Albert, Marburg; I. Bauerfeind, Landshut; J. Bischoff, Dessau; J.-U. Blohmer, Berlin; W. Budach, Düsseldorf; P. Dall, Lüneburg; I.J. Diel, Mannheim; N. Ditsch, Munich; P. Fasching, Erlangen; T. Fehm, Düsseldorf; M. Friedrich, Krefeld; B. Gerber, Rostock; V. Hanf, Fürth; N. Harbeck, Munich; J. Huober, Ulm; C. Jackisch, Offenbach; W. Janni, Ulm; H. Kreipe, Hanover; T. Kühn, Esslingen; S. Kümmel, Essen; C. Liedtke, Berlin; S. Loibl, Neu-Isenburg; H.-J. Lück, Hannover; D. Lüftner, Berlin; M. Lux, Erlangen; N. Maass, Kiel; V. Möbus, Frankfurt/M.; V. Müller, Hamburg; M. Müller-Schimpfle, Frankfurt; C. Mundhenke, Kiel; U. Nitz, Mönchengladbach; K. Rhiem, Köln; A. Rody, Lübeck; M. Schmidt, Mainz; A. Schneeweiss, Heidelberg; F. Schütz, Heidelberg; P. Sinn, Heidelberg; C. Solbach, Frankfurt am Main; E. Solomayer, Homburg; E. Stickeler, Aachen; M. Thill, Frankfurt/M.; C. Thomssen, Halle (Saale); M. Untch, Berlin; F. Wenz, Mannheim; I. Witzel, Hamburg; A. Wöckel, Würzburg

BreastCare
Multidisciplinary Journal for Research, Diagnosis and Therapy

Clinical Information

DOI: 10.1159/000489329

Suppl. table 1. AGO grades of recommendation

++	This investigation or therapeutic intervention is highly beneficial for patients, can be recommended without restriction, and should be performed.
+	This investigation or therapeutic intervention is of limited benefit for patients and can be performed.
+/–	This investigation or therapeutic intervention has not shown benefit for patients and may be performed only in individual cases. According to current knowledge, a general recommendation cannot be given.
–	This investigation or therapeutic intervention can be of disadvantage for patients and might not be performed.
–/–	This investigation or therapeutic intervention is of clear disadvantage for patients and should be avoided or omitted in any case.

BreastCare
Multidisciplinary Journal for Research, Diagnosis and Therapy

Clinical Information

DOI: 10.1159/000489329

Suppl. fig. 1. Indications for SNB indicating also the limited value of lymphoscintigraphy.



BreastCare
Multidisciplinary Journal for Research, Diagnosis and Therapy

Clinical Information

DOI: 10.1159/000489329

Suppl. fig. 2. An algorithm for decision making in cases with an indication for breast reconstruction.



BreastCare
Multidisciplinary Journal for Research, Diagnosis and Therapy

Clinical Information

DOI: 10.1159/000489329

Suppl. fig. 3. Subtype-specific strategies for systemic treatment indicating the recommendation to add pertuzumab only among cases with increased risk.



BreastCare
Multidisciplinary Journal for Research, Diagnosis and Therapy

Clinical Information

DOI: 10.1159/000489329

Suppl. fig. 4. Recommendation for adjuant therapy with trastuzumab +/- pertuzumab.



Adjuvant Treatment with Trastuzumab +/- Pertuzumab

	Oxford		
	LoE	GR	AGO
Trastuzumab	1a	A	++
▪ **Trastuzumab + Pertuzumab**			
▪ **N+ and / or HR-**	1b	B	+
▪ **N- and HR+**	1b	B	+/-
▪ **Trastuzumab in node-negative disease (if chemotherapy is indicated)**			
▪ 10 mm	1a	A	++
▪ > 5–10 mm	2b	B	+
▪ ≤ 5 mm	2b	B	+/-

BreastCare
Multidisciplinary Journal for Research, Diagnosis and Therapy

Clinical Information

DOI: 10.1159/000489329

Suppl. fig. 5. Recommendations for radiotherapy following NACT.



Radiotherapy following NACT

Pretreatment	Posttreatment	RT-BCS	PMRT	RT-RN	Oxford LoE	Oxford GR	AGO
Locally advanced	pCR / no pCR	yes	yes	yes	1a/1a/1a	A/A/A	++/++/++
cT1/2 cN1+	ypT1+ o. ypN1 + (no pCR)	yes	yes	yes	1a/2b/2b	A/B/B	++/+/+
cT1/2 cN1+	ypT0/is ypN0	yes	Increased risk of relapse[1]		2b/2b/2b	B/B/B	+/+/+
cT1/2 cN0 (Sonogr.bligat)	ypT0/is ypN0	Ja	nein	nein	2b/2b/2b	A/B/B	+/-/-

Locally advanced: T3-4 or cN2-N3,
BCS: Breast conserving surgery, PMRT: Post mastectomy radiotherapy, RN: Regional nodes
[1] Criteria for increased risk of relapse:

- pN0 premenopausal high risk: central or medium tumor localization, and (G2-3 and ER/PgR-negative)
- pretreatment pN1a/ cN+* high risk: central or medium tumor localization and (G2-3 or ER/PgR-negative) or premenopausal, lateral tumor localization and (G2-3 or ER/PgR-negative)

* = confirmed by core biopsy

BreastCare
Multidisciplinary Journal for Research, Diagnosis and Therapy

Clinical Information

DOI: 10.1159/000489329

Suppl. fig. 6. Ovarian protection and fertility preservation in premenopausal patients receiving (neo-)adjuvant chemotherapy (CT).



BreastCare
Multidisciplinary Journal for Research, Diagnosis and Therapy

Clinical Information

DOI: 10.1159/000489329

Suppl. fig. 7. Recommendations for treatment of metaplastic breast cancer.



BreastCare
Multidisciplinary Journal for Research, Diagnosis and Therapy

Clinical Information

DOI: 10.1159/000489329

References

1. *www.cebm.net*
2. Empfehlungen Gynäkologische Onkologie Kommission Mamma, 2017; www.ago-online.
3. van Gemert WA, Lanting CI, Goldbohm RA, et al. The proportion of postmenopausal breast cancer cases in the Netherlands attributable to lifestyle-related risk factors. Breast Cancer Res Treat. 2015;152:155-162
4. Bao PP, Zhao GM, Shu XO, et al., Modifiable Lifestyle Factors and Triple-negative Breast Cancer Survival: A Population-based Prospective Study. Epidemiology. 201;26:909-916
5. Robson M, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation N Engl J Med 2017;377:523-533
6. Couch FJ, Shimelis H, Hu C, et al. Associations between cancer predisposition testing panel genes and breast cancer JAMA Oncol 2017;3:1190-1196; Hauke J, et al. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer Med. 2018 Mar 9. doi: 10.1002/cam4.1376. [Epub ahead of print]
7. Plon SE, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Human mutation. 2008;29(11):1282-91
8. von Minckwitz G, Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014 Jun;15(7):747-56
9. Robson M, et al. Olaparib for Metastatic Breast Cancer in patients with a Germline *BRCA* Mutation N Engl J Med 2017;377:523-533
10. Sankatsing VDV et al. The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up. Int J Cancer. 2017 Aug 15;141(4):671-677
11. Oeffinger KC, Fontham ETH, Etzioni R, Herzig A, Michaelson JS et al Breast Cancer Screening for women at average risk. 2015 Guideline Update from the American Cancer Society. JAMA 2015; 314:1599-1614
12. ECIBC 2016. European Commission on Breast Cancer: Statements. Abruf Evidencereport update 24/11/2016, Zugriff 20122016: http://ecibc.jrc.ec.europa.eu/recommendations/list/3

DOI: 10.1159/000489329

13. Lauby-Secretan B, Scoccianti C, Loomis D, et al; International Agency for Research on Cancer Handbook Working Group: Breast-cancer screening–viewpoint of the IARC Working Group. N Engl J Med 2015;372:2353-2358
14. Nelson HD, et al. (2016a). Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2016 Feb 16;164(4):244-55
15. Nelson HD, et al. (2016b). Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2016 Feb 16;164(4):256-67
16. USPSTF 2016: US Preventive Services Task Force Final Recommendation Statement for mammographyScreening12.01.2016
17. http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/breast-cancer-screening Zugriff 04112016
18. IACR Handbook 2016: Website for the IARC publications: http://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Breast-Cancer-Screening-2016
19. Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age Trial at 17 years follow-up: a randomised controlled trial. Lancet Oncol 2015;16:1123-3
20. ACS 2015: Systematic Review of Cancer Screening Literature for Updating American Cancer Society Breast Cancer Screening Guidelines. Duke Evidence Synthesis Group. http://www.cancer.org/acs/groups/content/documents/document/acspc-046315.pdf. Zugriff am 11.August 2016
21. Skaane P, Bandos AI, Gullien R et al Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population –based screening program. Radiology 2013;267(1) 47-56
22. Skaane P, Bandos AI, Eben EB, Jebsen IN, Krager M, Haakenaasen U, Ekseth U, Izadi M, Hofwind S, Gullien R Two-view breast tomosynthesis screening with synthetically reconstructed projection images; Comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology 2014:271(3)655-663
23. Caumo F, Bernardi D, Ciatto S, Macaskill P, Pellegrini M, Brunelli S, Tuttobene P, Bricolo P, Fanto C, Valentini M, Montemezzi S, Houssami N Incremental effect from integrating 3D-

DOI: 10.1159/000489329

mammography (tomosynthesis) with 2D-mammography: Increased breast cancer detection evident for screening centres in a population-based trial. The Breast 2014;23:76-80

24. Friedewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM, Greenberg JS, Hayes MK, Copit DS,Carlson KL, Cink TM, Barke DO, Greer LN, Miller DP, Conant EF Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA 2014;311(24):2499-2507
25. Gilber FJ, Tucker L, Gillan MG, Willsher P, Cooke J, Duncan KA, Michell MJ, Dobson HM, Lim YY, Purushothaman H, Strudley C, Astley SM, Morrish O, Young KC, Duffy SW. The TOMMY trial: a comparison of TOMosynthesis with digital MammographY in the UK NHS Breast Screening Programme - a multicentre retrospective reading study comparing the diagnostic performance of digital breast tomosynthesis and digital mammography with digital mammography alone. Health Technol Assess. 2015 Jan;19(4):1-136.
26. Hodgson R, Heywang-Köbrunner SH, Harvey SC, et al. Systematic review of 3D mammography for breast cancer screening. Breast. 2016 Jun;27:52-61. doi: 10.1016/j.breast.2016.01.002
27. Melnikow J, Fenton JJ, Whitlock EP, Miglioretti DL, Weyrich MS, Thompson JH, Shah K. Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Service Task Force Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jan. Report No.: 14-05201-EF-3
28. Morel JC, Iqbal A, Wasan RK, Peacock C, Evans DR, Rahim R, Goligher J, Michell MJ. The accuracy of digital breast tomosynthesis compared with coned compression magnification mammography in the assessment of abnormalities found on mammography. Clin Radiol. 2014 Nov;69(11):1112-6
29. Cornford EJ, Turnbull AE, James JJ, Tsang R, Akram T, Burrell HC, Hamilton LJ, Tennant SL, Bagnall MJ, Puri S, Ball GR, Chen Y, Jones V. Accuracy of GE digital breast tomosynthesis vs supplementary mammographic views for diagnosis of screen-detected soft-tissue breast lesions. Br J Radiol. 2016;89(1058):20150735
30. American College of Radiology (ACR). D'Orsi CJ, Sickles EA, Mendelson EB et al. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. USA, Reston, VA: American College of Radiology; 2013
31. Müller-Schimpfle M. et al. BI-RADS die 5.–Eine Kurzmitteilung aus deutsch-/ österreichischer Sicht. Senologie - Zeitschrift für Mammadiagnostik und -therapie 2016; 13(03): 132-143

DOI: 10.1159/000489329

32. Melnikow J, Fenton JJ, Whitlock EP, Miglioretti DL, Weyrich MS, Thompson JH, Shah K. Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Service Task Force Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jan. Report No.: 14-05201-EF-3

33. Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, de Koning HJ, Kerlikowske K, Lehman CD, Tosteson AN. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med. 2015 Feb 3;162(3):157-66. doi: 10.7326/M14-0692

34. Tagliafico AS, Calabrese M, Mariscotti G, Durando M, Tosto S, Monetti F, Airaldi S, Bignotti B, Nori J, Bagni A, Signori A, Sormani MP, Houssami N. Adjunct Screening With Tomosynthesis or Ultrasound in Women With Mammography-Negative Dense Breasts: Interim Report of a Prospective Comparative Trial. J Clin Oncol 2016,35:1882-1888

35. El Sharouni M, Postma EL, Menezes GLG, van den Bosch M, Pijnappel RM, Witkamp AJ, van der Pol CC, Verkooijen HM, van Diest PJ High prevalence of MRI-detected contralateral and ipsilateral malignant findings in patients with invasive ductolobular breast cancer: Impact on surgical management. Clin Breast Cancer. 2016 Aug;16(4):269-75

36. Houssami N, Turner R, Morrow M. Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Ann Surg. 2013 Feb;257(2):249-55. doi: 10.1097/SLA.0b013e31827a8d17

37. Houssami N, Turner RM, Morrow M. Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer. Breast Cancer Res Treat. 2017 Sep;165(2):273-283

38. Piato JR, de Andrade RD, Chala LF, de Barros N, Mano MS, Melitto AS, Goncalves R, Soares Junior JM, Baracat EC, Filassi JR: MRI to Predict Nipple Involvement in Breast Cancer Patients. AJR Am J Roentgenol. 2016 May;206(5):1124-30

39. Luparia A, Mariscotti G, Durando M, Ciatto S, Bosco D, Campanino PP, Castellano I, Sapino A, Gandini G. Accuracy of tumour size assessment in the preoperative staging of breast cancer: comparison of digital mammography, tomosynthesis, ultrasound

DOI: 10.1159/000489329

and MRI.2013 Radiol Med Oct;118(7):1119-36

40. deSouza NM, Liu Y, Chiti A et al.: Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer. 2018 Jan 10Mar;91:153-163
41. Iwamoto T, Booser D, Valero V, et al.: Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. J ClinOncol 2012:30;729–734
42. Sanford RA, Song J, Gutierrez-Barrera AM et al., High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer. 2015;1;121:3422-3427
43. Deyarmin B et al. Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype. Ann Surg Oncol 2013;20:87–93
44. Yi M1, Huo L, Koenig KB, et al., Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol. 2014;25:1004-1011
45. Morrow M, Schnitt SJ, Norton L: Current management of lesions associated with an increased risk of breast cancer. Nat Rev Clin Oncol 2015;12:227-238
46. Lakhani SR, Ellis I, Schnitt S, Tan PH, van de Vijver M: WHO classification of tumours of the breast, ed 4th. Lyon, IARC Press, 2012
47. Renshaw AA, Gould EW: Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies. Pathology 2016;48:25-29
48. Menes TS, Kerlikowske K, Lange J, Jaffer S, Rosenberg R, Miglioretti DL: Subsequent breast cancer risk following diagnosis of atypical ductal hyperplasia on needle biopsy. JAMA Oncol 2017;3:36-41
49. Jean-Louis CJ, Masdon J, Smith B, Battles O, Dale P: The pathologic finding of combined lobular carcinoma in situ and invasive lobular cancer may indicate more than just a high-risk marker role of lobular carcinoma in situ. Am Surg 2017;83:482-485
50. Sinn P, Brucker SY, Budach W, Denkert C, Fehm T, Heitmann C, Kreipe H, Kühn T, Lebeau A, Schreer I: DCIS und Risikoläsionen; in Interdisziplinäre S3-Leitlinie für die

DOI: 10.1159/000489329

Diagnostik, Therapie und Nachsorge des Mammakarzinoms (Hrsg: Leitlinienprogramm Onkologie der AWMF, DKG und DKH), 2017, pp 79-89

51. Calhoun BC, Collins LC: Recommendations for excision following core needle biopsy of the breast: A contemporary evaluation of the literature. Histopathology 2016;68:138-151
52. Susnik B, Day D, Abeln E, Bowman T, Krueger J, Swenson KK, Tsai ML, Bretzke ML, Lillemoe TJ: Surgical outcomes of lobular neoplasia diagnosed in core biopsy: Prospective study of 316 cases. Clin Breast Cancer 2016;16:507-513
53. Ginter PS, D'Alfonso TM: Current concepts in diagnosis, molecular features, and management of lobular carcinoma in situ of the breast with a discussion of morphologic variants. Arch Pathol Lab Med 2017;141:1668-1678
54. Calhoun BC, Sobel A, White RL, Gromet M, Flippo T, Sarantou T, Livasy CA: Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies. Mod Pathol 2015;28:670-676
55. Schiaffino S, Gristina L, Villa A, Tosto S, Monetti F, Carli F, Calabrese M: Flat epithelial atypia: Conservative management of patients without residual microcalcifications post-vacuum-assisted breast biopsy. Br J Radiol 2018;91:20170484
56. Berry JS, Trappey AF, Vreeland TJ, Pattyn AR, Clifton GT, Berry EA, Schneble EJ, Kirkpatrick AD, Saenger JS, Peoples GE: Analysis of clinical and pathologic factors of pure, flat epithelial atypia on core needle biopsy to aid in the decision of excision or observation. J Cancer 2016;7:1-6
57. Villa A, Chiesa F, Massa T, Friedman D, Canavese G, Baccini P, Calabrese M, Tagliafico A: Flat epithelial atypia: Comparison between 9-gauge and 11-gauge devices. Clin Breast Cancer 2013;13:450-454
58. Tran HT, Mursleen A, Mirpour S, Ghanem O, Farha MJ: Papillary breast lesions: Association with malignancy and upgrade rates on surgical excision. Am Surg 2017;83:1294-1297
59. Saladin C, Haueisen H, Kampmann G, Oehlschlegel C, Seifert B, Rageth L, Rageth C, Stadlmann S, Kubik-Huch RA, Group M: Lesions with unclear malignant potential (b3) after minimally invasive breast biopsy: Evaluation of vacuum biopsies performed in

DOI: 10.1159/000489329

switzerland and recommended further management. Acta Radiol 2016;57:815-821

60. Choi SH, Jo S, Kim DH, Park JS, Choi Y, Kook SH, Chung EC, Lee SY: Clinical and imaging characteristics of papillary neoplasms of the breast associated with malignancy: A retrospective cohort study. Ultrasound Med Biol 2014;40:2599-2608
61. Wyss P, Varga Z, Rossle M, Rageth CJ: Papillary lesions of the breast: Outcomes of 156 patients managed without excisional biopsy. Breast J 2014;20:394-401
62. Swapp RE, Glazebrook KN, Jones KN, Brandts HM, Reynolds C, Visscher DW, Hieken TJ: Management of benign intraductal solitary papilloma diagnosed on core needle biopsy. Ann Surg Oncol 2013;20:1900-1905
63. Donaldson AR, Sieck L, Booth CN, Calhoun BC: Radial scars diagnosed on breast core biopsy: Frequency of atypia and carcinoma on excision and implications for management. Breast 2016;30:201-207
64. Matrai C, D'Alfonso TM, Pharmer L, Drotman MB, Simmons RM, Shin SJ: Advocating nonsurgical management of patients with small, incidental radial scars at the time of needle core biopsy: A study of 77 cases. Arch Pathol Lab Med 2015;139:1137-1142
65. Miller CL, West JA, Bettini AC, Koerner FC, Gudewicz TM, Freer PE, Coopey SB, Gadd MA, Hughes KS, Smith BL, Rafferty E, Specht MC: Surgical excision of radial scars diagnosed by core biopsy may help predict future risk of breast cancer. Breast Cancer Res Treat 2014;145:331-338
66. Conlon N, D'Arcy C, Kaplan JB, Bowser ZL, Cordero A, Brogi E, Corben AD: Radial scar at image-guided needle biopsy: Is excision necessary? Am J Surg Pathol 2015;39:779-785
67. Hahn M, Krainick-Strobel U, Toellner T, Gissler J, Kluge S, Krapfl E, Peisker U, Duda V, Degenhardt F, Sinn HP, Wallwiener D, Gruber IV, Minimally Invasive Breast Intervention Study Group of the German Society of S, Study Group for Breast Ultrasonography of the German Society for Ultrasound in M: Interdisciplinary consensus recommendations for the use of vacuum-assisted breast biopsy under sonographic guidance: First update 2012. Ultraschall Med 2012;33:366-371
68. American Cancer Society. Breast Cancer Facts and Figures 2015-2016. Atlanta: American Cancer Society 2015

DOI: 10.1159/000489329

69. Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1(7):888-896

70. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2012. Bethesda, MD: National Cancer Institute. November 2014 SEER data submission. http://seer.cancer.gov/csr/1975_2012/. Accessed September 23, 2015

71. Nadrljanski M, Milosevic Z, Plesinac-Karapandzic V et al. The role of breast magnetic resonance imaging in the diagnosisof ductal carcinoma in situ. Srp Arh Celok Lek. 2013;141:402-8

72. Fancellu et al. Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ BJS 2015; 102:883-893

73. Ryan R, Tawfik O, Jensen RA, Anant S. Current Approaches to Diagnosis and Treatment of Ductal Carcinoma IRyan R, Tawfik O, Jensen RA, Anant S. Current Approaches to Diagnosis and Treatment of Ductal Carcinoma In Situ and Future Directions. Prog Mol Biol Transl Sci. 2017;151:33-80

74. Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1(7):888-896

75. Morrow M et al. Society of Surgical Oncology- American Society for Radiation Oncology- American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Ductal Carcinoma In Situ JClin Onco2016; 34: 4040-4046

76. Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017;8(14):2653-2662

77. Miller AB, Wall C, Baines C, et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: a randomised screening trial BMJ. 2014;348:g366

78. Solin LJ, Gray R, Hughes LL, et al. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J

DOI: 10.1159/000489329

Clin Oncol 2015; 33:3938

79. Miller AB, Wall C, Baines C, et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: a randomised screening trial BMJ. 2014;348:g366

80. McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 2015; 33:709

81. Gluz O, Nitz U, Christgen M, Kates RE, Clemens M, Kraemer S, Nuding B, Aktas B, Kuemmel S, Reimer T, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Svedman C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N. Prospective WSG Phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score® result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2- high risk node-negative and –positive breast cancer patients. EBCC10, 2016

82. Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016 Aug 25;375(8):717-29

83. Stemmer SM, Steiner M, Rizel S, Soussan-Gutman L, Ben-Baruch N, Bareket-Samish A, Geffen DB, Nisenbaum B, Isaacs K, Fried G, Rosengarten O, Uziely B, Svedman C, McCullough D, Maddala T, Klang SH, Zidan J, Ryvo L, Kaufman B, Evron E, Karminsky N, Goldberg H, Shak S, Liebermann N. Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry. NPJ Breast Cancer. 2017 Sep 8;3:33. doi: 10.1038/s41523-017-0034-6

84. Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga J.

DOI: 10.1159/000489329

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol. 2016 Aug;27(8):1519-25

85. Fasching PA A, Loibl S, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Costa SD, Blohmer JU U, Fehm TN N, Huober J, Liedtke C, Müller V, Nekljudova V, Weber K, Rack B, Rübner M, Wang L, Ingle JN N, Weinshilboum RM M, von Minckwitz G, Couch F. BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study. SABCS 2015, abstract S5-06

86. Bidard F-C, Michiels S, Mueller V, Riethdorf S, Esserman LJ J, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA A, Hartkopf A, Generali D, Rothe F, Smerage J, Muinelo L, Stebbing J, Viens P, Magbanua M, Hall CS S, Engebråtenm O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran F-A, Cappelletti MR, Ignatiadis M, Name N, Proudhon C, Wolf D, Bowman Bauldry J, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Gopalkrishna Karhade M, Ruud Mathiesen R, Tokiniwa H, Llombart-Cussac A, D'Hollander K, Cottu P, Park JW W, Loibl S, Pierga J-Y, Pantel K. IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy. SABCS 2016, abstract S3-01

87. Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, Sagan C, Dupre PF, Body G, Giard S. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009 Feb 10;27726–32

88. Boughey JC, Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Feliberti EC, Hunt KK. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance). Ann Surg.

DOI: 10.1159/000489329

2016;263:802-807

89. Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013 Jun;14609–18

90. Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, Meterissian S, Arnaout A, Brackstone M, McCready DR, Karp SE, Trop I, Lisbona A, Wright FC, Younan RJ, Provencher L, Patocskai E, Omeroglu A, Robidoux A. Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study. J Clin Oncol. 2015;33258–264

91. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016 Apr 1;34(10):1072-8

92. Kümmel et al. Randomized surgical multicenter trial to evaluate the usefulness of lymphoscintigraphy (LSG) prior to sentinel node biopsy (SLNB) in early breast cancer: SenSzi (GBG80) trial. DOI: 10.1200/JCO.2017.35.15_suppl.555 *Journal of Clinical Oncology* 35, no. 15_suppl (May 2017) 555-555

93. Bertozzi N, Pesce M, Santi PL, Raposio E: Oncoplastic breast surgery: comprehensive review. Eur Rev Med Pharmacol Sci 2017;21(11):2572-2585

94. Singh N, Picha GJ, Hardas B, Schumacher A, Murphy DK: Five-Year Safety Data for More than 55,000 Subjects following Breast Implantation: Comparison of Rare Adverse Event Rates with Silicone Implants versus National Norms and Saline Implants. Plast Reconstr Surg 2017;140(4):666-679

95. Magill LJ, Robertson FP, Jell G, Mosahebi A, Keshtgar M: Determining the outcomes of post-mastectomy radiation therapy delivered to the definitive implant in patients

DOI: 10.1159/000489329

undergoing one- and two-stage implant-based breast reconstruction: A systematic review and meta-analysis. J Plast Reconstr Aesthet Surg 2017;70(10):1329-1335

96. Jagsi R, Momoh AO, Qi J, Hamill JB, Billig J, Kim HM, Pusic AL, Wilkins EG: Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction. J Natl Cancer Inst 2018;110(2)

97. Kuerer HM, Cordeiro PG, Mutter RW. Optimizing Breast Cancer Adjuvant Radiation and Integration of Breast and Reconstructive Surgery.Am Soc Clin Oncol Educ Book. 2017;37:93-105. doi: 10.14694/EDBK_175342.

98. Cohen O, Lam G, Karp N, Choi M: Determining the Oncologic Safety of Autologous Fat Grafting as a Reconstructive Modality: An Institutional Review of Breast Cancer Recurrence Rates and Surgical Outcomes. Plast Reconstr Surg 2017;140(3):382e-392e

99. Rastogi P, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008: 26; 778

100. Cortazar P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014: 384; 164

101. Berruti A, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol 2014: 32; 3883

102. EBCTCG: Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol pii: S1470-2045(17)30777-5, 2017

103. Von Minckwitz G, et al "Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)" SABCS 2015; Abstract S2-04

104. Sikov WM, Berry DA, Perou CM, et al: Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete

DOI: 10.1159/000489329

Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). J Clin Oncol, 2014

105. Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Darb-Esfahani S, Schmitt WD, Dan Costa S, Gerber B, Engels K, Nekljudova V, Loibl S, von Minckwitz G; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 2016 Mar;17(3):345-56)

106. Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. JAMA Oncol. 2018 Mar 1;4(3):302-308

107. Gianni L, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012: 13; 25-32

108. Gianni L et al. Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P). J Clin Oncol 33, 2015 (suppl; abstr 505)

109. Schneeweiss A et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 89:27-35, 2017

DOI: 10.1159/000489329

110. Hurvitz SA, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2017. pii: S1470-2045(17)30716-7

111. Swain SM, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol 2017. doi: 10.1093/annonc/mdx773

112. Von Minckwitz G, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2013: 31; 3623-30

113. Masuda N, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 376, 2147–2159, 2017

114. Ingold Heppner B, et al. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clin Cancer Res. 2016 Dec 1;22(23):5747-5754

115. Loibl S, et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (Her2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014: 32; 3212

116. Loibl S, Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clin Cancer Res. 2016 1;22(11):2675-83

117. Loibl S, PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol. 2016;27(8):1519-25

118. Kühn T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013

DOI: 10.1159/000489329

119. Boughey JC et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013: 310; 1455-1461

120. Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, Sagan C, Dupre PF, Body G, Giard S. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion. J Clin Oncol. 2009 Feb 10;27(5):726-32

121. El Hage Chehade H, Headon H, El Tokhy O, Heeney J, Kasem A, Mokbel K.Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am J Surg. 2016 Nov;212(5):969-981

122. Loibl S, et al. Impact in delay of start of chemotherapy and surgery on pCR and survival in breast cancer – a pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials. ASCO 2017 (abs 171)

123. Sanford RA, Lei X, Barcenas CH, Mittendorf EA, Caudle AS, Valero V, et al. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Ann Surg Oncol 2016;23(5):1515-21

124. Omarini C, et al. Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients. Eur J Surg Oncol 43(4):613-618, 2017

125. Pan H, Gray R, Braybrooke J, Davis C, Taylor C, McGale C, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF: 20-year risks of breast recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017;377:1836-1849

126. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al.: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805–816

127. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive

DOI: 10.1159/000489329

breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262–1271

128. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al.: Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015;372:436–446

129. Saha P, Regan MM, Pagani O et al.: Treatment efficacy, adherence, and quality of life among younger than 35 years in the International Breast Cancer Study Group Text ans SOFT adjuvant endocrine therapy trial. J Clin Oncol 2017;35:3113-3122

130. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, et al.: Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341–1352

131. Rydén L, Heibert Arnlind M, Vitols S, Höistad M, Ahlgren J: Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo – meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast 2016;26:106–114

132. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al.: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805–816

133. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al.: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262–1271

134. Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al.: Extending Aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016;375:209–219

135. Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, et al.: Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. Ann Oncol 2016;27:806–812

DOI: 10.1159/000489329

136. Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E et al.: Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst 2018;110;djx134

137. Tjan-Heijnen V, van Hellemond I, Peer P et al.: Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol 2017; 18: 1502–11

138. Joseph A. Sparano, Fengmin Zhao, Silvana Martino, Jennifer A. Ligibel, Edith A. Perez, Tom Saphner, Antonio C. Wolff, George W. Sledge Jr, William C. Wood, and Nancy E. Davidson. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. JCO2015; 33: 2353-2360

139. Perrone F, Nuzzo F, Di Rella F, et al. Weekly docetaxel versus cmf as adjuvant chemotherapy for older women with early breast cancer: Final results of the randomized phase iii elda trial. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2015;26:675–682

140. Shulman LN, Berry DA, Cirrincione CT, et al., Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014;32:2311-2317

141. Gray R et al. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials. SABCS 2017, abstr. GS1-01

142. Moebus V, Jackisch C, Lueck HL et al. Ten-years results of intense dose-dense chemotherapy show superior survival compared with a ceonventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol 2018;29:178-185

143. von Minckwitz G et al; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122-131

DOI: 10.1159/000489329

144. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al., 2 years versus 1 year of adjuvant trastuzumab for her2-positive breast cancer (hera): An open-label, randomised controlled trial. Lancet 2013;382:1021–1028

145. Joensuu H et al. A randomized phase III study of a adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study). SABCS 2017, abstr. GS3-04

146. Pivot X et al.; PrefHer Study Group. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. Eur J Cancer. 2017;86:82-90

147. Jackisch C, Hegg R, Stroyakovskiy D et al. HannaH phase III randomized study: Association of total pathologic complete response with event-free survival in Her2-positive early breast cancer treated with neoadjuvnat-adjuvant trastuzumab after 2 years of treatment-free follow up. Eur J Cancer 2016;62:62-75

148. Tolaney SM et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134-41, Tolaney SM et al. Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Journal of Clinical Oncology 2017;35:15 suppl: 511-511

149. Thill M et al. Einführung und Verwendung von biosimilaren Antikörpern in der Therapie des Mammakarzinoms. Geburtshilfe Frauenheilkd 2018;78(1):41-44

150. Thill M. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer. Expert Rev Anticancer Ther. 2015;15(3):331-8

151. Tabernero J et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2017;1(6):e000142

152. Jacobs I, Ewesuedo R, Lula S, Zacharchuk C. Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence. BioDrugs. 2017;31(1):1-36

DOI: 10.1159/000489329

153. Wenz F, Sperk E, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Fussl C, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). Strahlenther Onkol. 2014 Aug; 190705–14

154. Sautter-Bihl ML, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau R, Fussl C, Haase W, Harms W, Piroth MD, Souchon R, Wenz F, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). Strahlenther Onkol. 2014 Apr; 190342–51

155. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR; START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013 Oct;141086–94

156. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann 7, Senn HJ; Panel Members. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug;261533–46

157. Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015:A Brief Summary of the Consensus Discussion. Breast Care (Basel). 2015 Apr;10124–30

158. Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS, McCormick B, McQueen JR, Pierce LJ, Powell SN, Recht A, Taghian AG, Vicini FA, White JR, Haffty BG. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011 Sep 1;8159–68

159. Harris JR. Critical Decision-Making in Radiation Therapy for Breast Cancer. Presentation at the San Antonio Breast Cancer Symposium 2015. Cancer Res February 15, 2016 76:PL1–01

160. Yarnold J. Hypofractionated radiotherapy in early breast cancer: clinical, dosimetric and radio-genomic issues. Breast 2015;24(Suppl 1): PG 10.01

DOI: 10.1159/000489329

161. Whelan T. Tailoring or omitting radiotherapy in early breast cancer. Cancer Res February 15, 2016 76:ES6–2

162. Bartelink H, Maingon P, Poortmans P, et al.; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015 Jan;1647–56

163. Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013 Jul 1;312382–7

164. EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014 Jun 21;383[9935]:2127–35

165. Kyndi M, Overgaard M, Nielsen HM, Sørensen FB, Knudsen H, Overgaard J. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol. 2009 Jan;9074–9

166. Truong PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E. Selecting breast cancer patients with T1-T2 tumours and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Apr 1;611337–47

167. Shen H, Zhao L, Wang L, Liu X, Liu X, Liu J, Niu F, Lv S, Niu Y. Postmastectomy radiotherapy benefit in Chinese breast cancer patients with T1-T2 tumour and 1–3 positive axillary lymph nodes by molecular subtypes: an analysis of 1369 cases. Tumour Biol. 2015 Dec

DOI: 10.1159/000489329

168. Poortmans PM, Collette S, Kirkove C, et al.; EORTC Radiation Oncology and Breast Cancer Groups. Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. N Engl J Med. 2015 Jul 23;373317–27

169. Whelan TJ, Olivotto IA, Parulekar WR, et al.; MA.20 Study Investigators. Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med. 2015 Jul 23;373307–16

170. Thorsen LB, Offersen BV, Danø H, et al. DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. J Clin Oncol. 2016 Feb 1;34314–20

171. Budach W, Bölke E, Kammers K, Gerber PA, Nestle-Krämling C, Matuschek C. Adjuvant radiation therapy of regional lymph nodes in breast cancer – a meta-analysis of randomized trials- an update. Radiat Oncol. 2015 Dec 21;10:258

172. Chien TJ, Hsu CH, Liu CY et al.: Effect of acupuncture on hot flush and menopause symptoms in breast cancer- A systematic review and meta-analysis. PLoS One. 2017;12(8):e0180918

173. Hershman DL, Unger JM, Greenlee H et al.: Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer (S1200). San Antonio Breast Cancer Conference 2017; Abstract GS4-04

174. Leonard RCF, Adamson DJA, Bertelli G et al.: GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017 Aug 1;28(8):1811-1816

175. Fréour T, Barrière P, Masson D. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. Eur J Cancer. 2017 Mar;74:1-8. doi: 10.1016/j.ejca.2016.12.008

176. Gambacciani M, Levancini M. Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause. 2017;24(3):316-9

177. Witt CM et al. A Comprehensive Definition for Integrative Oncology. J Natl Cancer Inst Monogr 2017(52): lgx012

DOI: 10.1159/000489329

178. Chien TJ, Hsu CH, Liu CY, et al. Effect of acupuncture on hot flush and menopause symptoms in breast cancer- A systematic review and meta-analysis. PLoS One. 2017 Aug 22;12(8):e0180918

179. Hershman DL, Unger JM, Greenlee H, et al. Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer (S1200). Presented at: 2017 San Antonio Breast Cancer Symposium; Dec. 5-9, 2017; San Antonio, TX. Abstract GS4-04

180. Zick SM, Sen A, Wyatt GK, et al. Investigation of 2 Types of Self-administered Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors: A Randomized Clinical Trial. JAMA Oncol. 2016 Nov 1;2(11):1470-1476. doi: 10.1001/jamaoncol.2016.1867

181. Zhang B, Dong JN, Sun P, et al. Effect of therapeutic care for treating fatigue in patients with breast cancer receiving chemotherapy. Medicine (Baltimore). 2017 Aug;96(33):e7750

182. Haller H, Winkler MM, Klose P, Dobos G, Kuemmel S, Cramer H: Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. Acta oncologica (Stockholm, Sweden). 2017 Jul 07:1-12. PubMed PMID: 28686520

183. Steindorf K, Wiskemann J, Ulrich CM, Schmidt ME: Effects of exercise on sleep problems in breast cancer patients receiving radiotherapy: a randomized clinical trial. Breast Cancer Res Treat. 2017; 162(3):489-499

184. Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ: Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. The Cochrane database of systematic reviews. 2017 Jan 03;1:CD010802. PubMed PMID: 28045199

185. Irwin MR, Olmstead R, Carrillo C, Sadeghi N, Nicassio P, Ganz P A Bower JE: Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial . .J Clin Oncol. 2017 Aug 10;35(23):2656-2665

DOI: 10.1159/000489329

186. Loibl S, Schmidt A, Gentilini O, Kaufman B, Kuhl C, Denkert C, von Minckwitz G, Parokonnaya A, Stensheim H, Thomssen C, van Calsteren K, Poortmans P, Berveiller P, Markert UR, Amant F. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA Oncol. 2015 Nov;1(8):1145-53

187. Peccatori FA, Codacci-Pisanelli G, Del Grande M, Scarfone G, Zugni F, Petralia G. Whole body MRI for systemic staging of breast cancer in pregant women. Breast. 2017 Oct;35:177-181

188. Köhler C, Oppelt P, Favero G, Morgenstern B, Runnebaum I, Tsunoda A, Schmittel A, Schneider A, Mueller M, Marnitz S. How much platinum passes through the placental barriers? Analysis of platinum applications in 21 patients with cervical cancer during pregnancy. Am J Obstet Gynecol. 2015 Aug;213(2):206

189. Chen H , Wu K, Wang M, Wang F, Zhang M, Zhang P. A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18. Breast. 2017 Oct;35:48-54

190. Hessler LK, Molitoris JK, Rosenblatt PY, Bellavance EC, Nichols EM, Tkaczuk KHR, Feigenberg SJ, Bentzen SM, Kesmodel SB. SFactors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database. Surg Oncol 2017 Oct;24(10):2907-2914

191. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of tumors of the breast. World Health Organization classification of tumours. 4th ed. Lyon: IARC Press; 2012. 48–52 pp

192. Sinn HP, Kreipe H. A brief overview of the WHO classification of breast tumors, 4th edition, focusing on issues and updates from the 3rd edition. Breast Care (Basel) 2013; 8:149-54

193. Song Y, Liu X, Zhang G, Song H, Ren Y, He X, et al. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol. 2013; 11:129

DOI: 10.1159/000489329

194. Zhang Y, Lv F, Yang Y, Qian X, Lang R, Fan Y, Liu F, Li Y, Li S, Shen B, Pringle GA, Zhang X, Fu L, Guo X, Clinicopathological Features and Prognosis of Metaplastic Breast Carcinoma: Experience of a Major Chinese Cancer Center, PLoS One. 2015 Jun 26;10(6):e0131409

195. Pezzi CM, Patel-Parekh L, Cole K, et al (2007). Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol, 14, 166-73

196. J. D. Beatty, M. Atwood, R. Tickman, and M. Reiner, "Metaplastic breast cancer: clinical significance," American Journal of Surgery, vol. 191, no. 5, pp. 657–664, 2006

197. Tzanninis IG et al., Management and Outcomes in Metaplastic Breast Cancer Clin Breast Cancer. 2016 Dec;16(6):437-443

198. Tseng WH, Martinez SR. Metaplastic breast cancer: to radiate or not to radiate? Ann Surg Oncol 2011; 18:94-103

199. Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, Cardoso F: Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 2017;75:284-298.

200. Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C; Chemo-N 0 Study Group: Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013;49(8):1825-35.

201. Galimberti V, Ribeiro Fontana SK, Maisonneuve P, Steccanella F, Vento AR, Intra M, Naninato P, Caldarella P, Iorfida M, Colleoni M, Viale G, Grana CM, Rotmensz N, Luini A: Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol 2016 Mar;42(3):361-8.

202. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F,

DOI: 10.1159/000489329

Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group: Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18(12):1688-1700.